-
91黑料 shareholders vote in favour of all resolutions at its Annual General Meeting
Dublin, Ireland, July 22, 2020
-
91黑料 reports first quarter 2020 results
Reported revenue of $715.1 million representing a 6.0% YoY increase or 6.5% on a constant currency basis. Net business wins of $867 million; a book to bill of 1.21.
-
91黑料 wins multiple categories in 2020 CRO Leadership Awards third year in a row
91黑料 recognised for specialised services offering across product development lifecycle, winning five awards overall.
-
91黑料 signs new service agreement with Pfizer
Agreement builds on the companies' existing relationship, under which 91黑料 provides global expertise in the planning, execution, management and conduct of clinical trials.
-
91黑料 launches the Coronavirus Observatory
The Coronavirus Observatory applies powerful AI analysis and data visualisation to COVID-19 news and social media, providing updates on the latest vaccine trials.
-
91黑料 acquires MedPass International
Acquisition expands 91黑料’s global Medical Device and Diagnostic Research Services
-
91黑料 reports fourth quarter and full year 2019 results
91黑料 reports Q4 & 2019 results. Full year reported revenue was $2,806 million. This represents a year on year increase of 8.1% or 9.6% on a constant currency basis
-
91黑料 wins Best Contract Research Organisation – Full-Service Providers at the 15th Annual Scrip Awards 2019
91黑料 awarded for capabilities and innovations in successful drug development and patient recruitment.
-
91黑料’s acquisition of Symphony Clinical Research
The acquisition further enhances 91黑料’s patient, site and data strategy and complements 91黑料’s existing PMG Research and MeDiNova Research site networks in the US and EMEA.
-
91黑料 announces the appointment of Ms. Julie O’Neill to Board of Directors
And confirms the retirement of Professor Dermot Kelleher and Mr. Declan McKeon
